Faculty
Amanda Cashen.jpg

Amanda F. Cashen, MD

Associate Professor
Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Lymphoma
  • Leukemia
  • Myelodysplastic syndromes
  • Stem cell transplantation

Contact

  • 314-454-8306 (tel)
  • 314-454-7551 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8007
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Manuscripts

  • Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 May 11;129(19):2680-2692
  • Phase I/II study of intravenous plerixafor added to a mobilization regimen of G-CSF in lymphoma patients undergoing autologous stem cell collection
    Cashen A, Rettig M, Gao F, Smith A, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J
    Biol Blood Marrow Transplant 2017 May 2; [Epub ahead of print]
  • Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
    Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, Heath S, Elliott K, Reineck T, Fulton RS, Fronick CC, O'Laughlin M, Ganel L, Abboud CN, Cashen AF, DiPersio JF, Wilson RK, Link DC, Welch JS, Ley TJ, Graubert TA, Westervelt P, Walter MJ
    Leukemia 2017 Apr;31(4):872-881
  • Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
    Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP
    Lancet Haematol 2017 Apr;4(4):e176-e182
  • Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy
    Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, Gao F, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Jacoby MA, Cashen AF, Wartman LD, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ, Welch JS
    Blood 2017 Mar 9;129(10):1397-1401
  • RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106
    Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW
    Br J Haematol 2017 Mar;176(5):759-769
  • Longitudinal body composition changes in diffuse large B-cell lymphoma survivors: a retrospective cohort study of United States veterans
    Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR
    J Natl Cancer Inst 2016 Jul 5;108(11):djw145
  • Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma - a "real world" study
    Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS
    Hematol Oncol 2017 Jan 8; [Epub ahead of print]
  • TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Phase II study of propylene glycol-free melphalan combined with carmustine, etoposide, and cytarabine for myeloablative conditioning in lymphoma patients undergoing autologous stem cell transplantation
    Cashen AF, Fletcher T, Ceriotti C, Gao F, Ghobadi A, Vij R, Stockerl-Goldstein K, DiPersio J, Abboud C
    Biol Blood Marrow Transplant 2016 Dec;22(12):2155-2158
  • A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome
    Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R
    Leuk Lymphoma 2016 Nov;57(11):2535-2540
  • Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward
    Ali AM, Dehdashti F, DiPersio JF, Cashen AF
    Blood Rev 2016 Sep;30(5):389-99
  • HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • Graft-versus-lymphoma effect can be rapid and potent in diffuse large B-cell lymphoma
    Rashidi A, Cashen A
    Exp Clin Transplant 2016 Aug;14(4):460-2
  • NKG2D-NKG2D ligand interaction inhibits the outgrowth of naturally arising low-grade B cell lymphoma in vivo
    Raju S, Kretzmer LZ, Koues OI, Payton JE, Oltz EM, Cashen A, Polic B, Schreiber RD, Shaw AS, Markiewicz MA
    J Immunol 2016 Jun 1;196(11):4805-13
  • Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest
    Ali AM, Mirrakhimov AE, Abboud CN, Cashen AF
    Hematol Oncol 2016 Jun;34(2):69-78
  • Peritransplant serum albumin decline predicts subsequent severe acute graft-versus-host disease after mucotoxic myeloablative conditioning
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Cashen AF, Pusic I, Romee R
    Biol Blood Marrow Transplant 2016 Jun;22(6):1137-41
  • Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis
    Rashidi A, Ebadi M, Cashen AF
    Bone Marrow Transplant 2016 Apr;51(4):521-528
  • A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia
    Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R
    Leuk Lymphoma 2016 Mar;57(3):728-730
  • The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas
    Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA
    Clin Cancer Res 2016 Feb 1;22(3):596-608
  • Early post-transplant contrast-enhanced abdominopelvic CT scan predicts the risk of subsequent acute GvHD
    Rashidi A, Lin MF, Cashen AF
    Bone Marrow Transplant 2016 Jan;51(1):150-2
  • A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma
    Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M
    Bone Marrow Transplant 2015 Nov;50(11):1416-1423
  • High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-hodgkin lymphoma: feasible, but for which patients?
    Wildes TM, Cashen A
    J Geriatr Oncol 2015 Sep;6(5):344-5
  • Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome
    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2015 Oct;21(10):1761-9
  • Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma
    Rashidi A, Cashen AF
    Blood Cancer J 2015 Jun 5;5:e318
  • Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
    Rashidi A, Cashen AF
    Future Oncol 2015 Jun;11(11):1659-64
  • Impact of pretransplantation (18)F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M
    Center for International Blood and Marrow Transplant Research Lymphoma Working Committee

    Biol Blood Marrow Transplant 2015 Sep;21(9):1605-11
  • Cytogenetic patterns of relapse following allogeneic stem cell transplantation in morphologic complete remission in patients with acute myeloid leukemia
    Rashidi A, Cashen AF
    Leuk Res 2015 Jun;39(6):553-4
  • Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma
    Koues OI, Kowalewski RA, Chang LW, Pyfrom SC, Schmidt JA, Luo H, Sandoval LE, Hughes TB, Bednarski JJ, Cashen AF, Payton JE, Oltz EM
    Immunity 2015 Jan 20;42(1):186-198
  • A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission
    Rashidi A, Cashen AF
    Leuk Res 2015 Jan;39(1):77-81
  • Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure
    Ghobadi A, Nolley E, Liu J, McBride A, Stockerl-Goldstein K, Cashen A
    Bone Marrow Transplant 2015 Jan;50(1):134-136
  • A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma
    Wang TF, Fiala MA, Cashen AF, Uy GL, Abboud CN, Fletcher T, Wu N, Westervelt P, DiPersio JF, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2014 Nov;49(11):1366-70
  • A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma
    Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W
    Biol Blood Marrow Transplant 2014 Jul;20(7):951-9
  • Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
    Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, Gallamini A, Siegel BA, Cashen AF, Vera P, Tilly H, Versari A, Itti E
    Eur J Nucl Med Mol Imaging 2014 Nov;41(11):2017-22
  • Prognostic significance of [18F]fluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: a retrospective analysis
    Shea L, Liu J, Cashen A
    Leuk Lymphoma 2015 Jan;56(1):256-9
  • Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia
    Jacoby MA, Martin MG, Uy GL, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN
    Am J Hematol 2014 May;89(5):487-92
  • Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4
    Liu H, Westergard TD, Cashen A, Piwnica-Worms DR, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ
    Cancer Cell 2014 Apr 14;25(4):530-42
  • Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML
    Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, Uy G, Cashen A, DiPersio JF, Abboud CN
    Int J Hematol 2014 Mar;99(3):272-8
  • Decitabine in the treatment of acute myeloid leukemia in elderly patients
    Malik P, Cashen AF
    Cancer Manag Res 2014 Feb 3;6:53-61
  • Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality
    Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN
    J Clin Oncol 2014 Feb 1;32(4):273-81
  • An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax
    Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Vera P, Tilly H, Siegel BA, Gallamini A, Casasnovas RO, Haioun C
    Eur J Nucl Med Mol Imaging 2013 Sep;40(9):1312-20
  • Therapy in primary mediastinal B-cell lymphoma
    Cashen AF, Christian BA, Bartlett NL
    N Engl J Med 2013 Jul 18;369(3):282-3
  • Assessment of cellular proliferation in tumors by PET using 18F-ISO-1
    Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, Wagner-Johnson N, Mach RH
    J Nucl Med 2013 Mar;54(3):350-7
  • A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
    Ramsingh G, Westervelt P, Cashen AF, Uy GL, Stockerl-Goldstein K, Abboud CN, Bernabe N, Monahan R, DiPersio JF, Vij R
    Leukemia 2013 Mar;27(3):725-8
  • The role of F18-flurodeoxyglucose positron emission tomography in the management of relapsed or refracotry Hodgkin's lymphoma
    Cashen A
    Oncol Hematol Rev (US) 2012;8(2):111-5
  • Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin
    Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR
    Leuk Lymphoma 2012 Nov;53(11):2283-6
  • Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature
    Chawla JS, Ghobadi A, Mosley J 3rd, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R
    Transpl Infect Dis 2012 Jun;14(3):259-67
  • A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
    Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF
    Blood 2012 Apr 26;119(17):3917-24
  • Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, Laplant B, Laumann K, Erlichman C, DiPersio J
    Ann Hematol 2012 Jan;91(1):33-8
  • Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma
    Foyil KV, Kennedy DA, Grove LE, Bartlett NL, Cashen AF
    Leuk Lymphoma 2012 Mar;53(3):506-7
  • A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    Blood 2011 Nov 10;118(19):5119-25
  • Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study
    Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R
    Am J Hematol 2011 Sep;86(9):796-800
  • Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study
    Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD
    J Clin Oncol 2011 Sep 1;29(25):3389-95
  • Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy
    Kreisel F, Kulkarni S, Kerns RT, Hassan A, Deshmukh H, Nagarajan R, Frater JL, Cashen A
    Cancer Genet 2011 Mar;204(3):129-137
  • Decitabine for the treatment of older patients with myelodysplastic syndrome and acute myelogenous leukemia
    Goyal SD, Cashen AF
    Aging Health 2011;7(3):363-378
  • 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of International Harmonization Project interpretation
    Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL
    J Nucl Med 2011 Mar;52(3):386-92
  • A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF
    J Clin Oncol 2010 Feb 1;28(4):556-61
  • Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R
    Am J Hematol 2009 Nov;84(11):733-7
  • A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
    Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, DiPersio JF, Vij R
    Am J Hematol 2009 Sep;84(9):560-4
  • Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG
    Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 Jul;44(1):13-7
  • Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells
    Cashen AF
    Drugs Today (Barc) 2009 Jul;45(7):497-505
  • Azacitidine: a review of its use in the management of myelodysplastic syndromes
    Lammers PE, Cashen AF
    Clinical Medicine: Therapeutics 2009; 1:1189-1197
  • Protein losing enteropathy associated with follicular lymphoma of the small bowel
    Cashen AF, Rubin DC, Bartlett NL
    Am J Clin Oncol 2009 Apr;32(2):222-3
  • Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
    Uy GL, Rettig MP, Cashen AF
    Expert Opin Biol Ther 2008 Nov;8(11):1797-804
  • A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma
    Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J
    Biol Blood Marrow Transplant 2008 Nov;14(11):1253-61
  • Salvage regimens for Hodgkin lymphoma
    Cashen AF, Bartlett NL
    Clin Adv Hematol Oncol 2008 Jul;6(7):517-24
  • Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF
    Biol Blood Marrow Transplant 2008 Sep;14(9):1045-56
  • Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J
    Cancer Chemother Pharmacol 2008 Apr;61(5):759-66
  • Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
    Cashen AF, Lazarus HM, Devine SM
    Bone Marrow Transplant 2007 May;39(10):577-88
  • Use of recombinant factor VIIa for hip surgery in a patient with factor-VII deficiency. A case report
    Gopalan PK, Clohisy JC, Cashen AF, Eby CS
    J Bone Joint Surg Am 2007 Feb;89(2):389-91
  • AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent
    Cashen AF, Nervi B, DiPersio J
    Future Oncol 2007 Feb;3(1):19-27
  • Therapy of relapsed Hodgkin lymphoma
    Cashen AF, Bartlett NL
    Blood Rev 2007 Sep;21(5):233-43
  • Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine
    Cashen AF, Devine H, DiPersio J
    Am J Hematol 2006 Jul;81(7):543-5
  • Cytokines and stem cell mobilization for autologous and allogeneic transplantation
    Cashen AF, Link D, Devine S, DiPersio J
    Curr Hematol Rep 2004 Nov;3(6):406-12
  • Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A, DiPersio JF, Khoury H
    J Clin Oncol 2003 Nov 15;21(22):4255-6
  • Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation
    Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A
    Oncogene 1999 Aug 5;18(31):4450-9
  • Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas
    Gutmann DH, Giordano MJ, Fishback AS, Guha A
    Neurology 1997 Jul;49(1):267-70
  • The effects of propofol on rat transcranial magnetic motor evoked potentials
    Fishback AS, Shields CB, Linden RD, Zhang YP, Burke D
    Neurosurgery 1995 Nov;37(5):969-74